ZYDUSLIFEZydus Lifesciences Limited
Convert to ideaPharmaceuticals & Biotechnology · Pharmaceuticals · CRISIL: AAA (Stable)
The verdict combines business quality, price and timing. Sign in free to see it.
Sign in freeDown 0.9 this quarter.
Momentum from moving averages, Supertrend and RSI.
5 forensic issues found. Sign in to see which.
Valuation Metrics
Q2 FY2027Intrinsic value, Graham number and DCF against today's price
5 found · risk elevated
Quality, growth, balance sheet and earnings quality behind the score
ⓘ Based on fundamental & forensic analysis. Always verify against official filings and consult a financial advisor.
Financial Metrics
Comparing Q2 FY2027 vs Q2 FY2026
| Quarter | Revenue | Net Profit | OPM | NPM | EPS | Int. Cover |
|---|---|---|---|---|---|---|
| Q2 FY2027 | ₹7910 Cr | ₹928 Cr | 16.31% | 11.73% | ₹9.28 | 7.6x |
| Q1 FY2027 | ₹8017 Cr | ₹990 Cr | 17.15% | 12.35% | ₹9.35 | 9.4x |
| Q4 FY2026 | ₹7587 Cr | ₹1341 Cr | 26.97% | 17.67% | ₹12.65 | 14.5x |
| Q3 FY2026 | ₹6865 Cr | ₹1023 Cr | 21.22% | 14.90% | ₹10.36 | 11.4x |
| Q2 FY2026 | ₹6123 Cr | ₹1239 Cr | 27.99% | 20.23% | ₹12.51 | 17.7x |
| Q1 FY2026 | ₹6574 Cr | ₹1521 Cr | 28.15% | 23.14% | ₹14.58 | 23.7x |
Momentum score, 1-year chart, moving averages, support and resistance.
Turnaround stage, and how each measure moved over 3 years against the company's own range.
Order wins, capex, pledges, rating actions and every material filing.
Management guidance, Q&A highlights and whether they delivered what they said.
The earnings call read across investor dimensions.
Promoter, FII and mutual fund holding, and what changed this quarter.
Similar-size peers in Pharmaceuticals
Compare with peers →Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses, as well as in the therapeutic areas of pain management, neurology, metabolic disorder, and neurology. In addition, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. Further, it develops and markets products for orthopaedic surgery, including pathologies affecting the hip and knee. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.
Note: This comprehensive analysis combines technical data, fundamental data, and investment thesis. Always do your own research and consider your personal risk tolerance before investing.